

THE FLORIDA SENATE  
2026 SUMMARY OF LEGISLATION PASSED  
**Committee on Health Policy**

**CS/CS/SB 1092 — Podiatric Medicine**

by Appropriations Committee on Health and Human Services; Health Policy Committee; and Senator Massullo

The bill limits the controlled substance prescribing continuing education requirement that applies to all podiatric physicians under preexisting law to only those podiatric physicians registered with the U.S. Drug Enforcement Administration for authorization to prescribe controlled substances, thereby exempting podiatric physicians who do not prescribe controlled substances.

The bill authorizes a podiatric physician to perform procedures using cellular or tissue-based products that have not been approved by the U.S. Food and Drug Administration (FDA), provided the podiatric physician meets specified criteria. Podiatric physicians using such products must provide written notice to patients, and include a disclaimer in all advertisements, disclosing that the treatment is not approved by the FDA. The Board of Podiatric Medicine is authorized to adopt rules to implement the bill.

If approved by the Governor, or allowed to become law without the Governor's signature, these provisions take effect upon becoming law.

*Vote: Senate 35-0; House 112-0*